Pursuing novel therapeutics targeting NASH with liver fibrosis

Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis.

Our Programs - Madrigal PharmaceuticalsOUR PROGRAMS
NASH - Madrigal PharmaceuticalsNASH
About Us - Madrigal PharmaceuticalsABOUT US

NEWS

June 25, 2022
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

June 06, 2022
Madrigal Pharmaceuticals Supports International NASH Day on June 9


PRESS RELEASES >

EVENTS

June 25, 2022
EASL Investor Event and Webcast

June 15, 2022
JMP Securities Life Sciences Conference

EVENTS & PRESENTATIONS >

NASH is a growing global health challenge. There are 22 million people living with NASH in the U.S. alone, and more than 8 million who have NASH with significant liver fibrosis.

Learn More